Enliven therapeutics reports fourth quarter and full year 2023 financial results and provides a business update

Initial proof of concept data from phase 1a trial evaluating elvn-001 in adults with chronic myeloid leukemia (cml) is expected in the second quarter of 2024

ELVN Ratings Summary

ELVN Quant Ranking